Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Digital Uts Ventures (DUTV) Message Board

This is totally off topic but I owned this company

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 17653
Posted On: 11/22/2014 1:36:27 PM
Avatar
Posted By: 2can
This is totally off topic but I owned this company long time ago but I wanted to put it up here because it has some good stuff in it.

Slow progress, retesting it's high, better margins and patent cliff expirations. if your bored it's not a bad read anyway. There are 4 pages

http://seekingalpha.com/article/2675255-why-r...l-retest-9

Why Rite Aid Will Retest $9

Nov. 12, 2014 4:08 PM ET | About: Rite Aid Corporation (RAD), Includes: CVS, WAG


Summary
•2 years left in patent cliff, which means higher margins for pharmacies.
•Generic introduction delays and supply chain problems are temporary; these problems forced RAD to lower EPS guidance.
•RAD is now a growing company.
•RAD is cheap relative to competitors.

Rite Aid Corporation (NYSE: RAD) shares surged from $1 to north of $8.50 in less than two years' time, but have since retraced to $5.50. While the stock has still performed well over the course of several years, there are three reasons in particular to suggest that shares will retest 52-week highs.

Continued benefits from patent cliff
Evaluate Pharma estimates that between 2011 and 2016 brand drugs will lose $133 billion in combined sales thanks to the expiration of patents, and the introduction of generics. This span is called the patent cliff. Following 2016, generic introductions will slow down, with Fisher Investments Research estimating just $18.3 billion in lost drug sales from 2016-2020.

That said, generic drugs create higher profits for pharmacies. There are many reasons, the first of which is a larger gap between wholesale and retail drug prices, thus increasing the pharmacy's share. The second reason is that generic drugs are almost always bought in bulk, thereby reducing logistical costs.



(0)
(0)




Digital Uts Ventures (DUTV) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us